ReviewDiscover oncology2025
Clinical applications of artificial intelligence in the histopathology of lymphoma: diagnosis, treatment and prognosis.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Artificial intelligence (AI) is an important branch of computer science. With the rapid development of AI, the application in oncology has become increasingly widespread. As a hematologic malignancy characterized by remarkable heterogeneity, lymphoma has long posed significant challenges in both diagnosis and treatment, particularly with regard to its complex classification and difficulties in prognostic evaluation. Breakthroughs in AI technology have provided a new paradigm for precision treatment of tumors. AI can integrate and analyze HE pathology slides and PET/CT images to enhance diagnostic efficiency; meanwhile, in terms of treatment prognosis, AI can identify biomarkers to accurately classify lymphoma subtypes for therapeutic guidance, simultaneously quantify biomarkers to minimize the influence of subjective variability, and predict the patients' prognosis based on the extracted features to assist in the precise treatment of lymphoma. This review aims to provide an overview of AI related to various fields of lymphoma, introducing the core technologies and principles of AI, including deep learning, decision trees, regression models, and so on. We also discuss the clinical applications of AI in lymphoma pathology slides and PET/CT images, systematically analyze the clinical applications of AI in diagnosis, treatment, and prognosis, as well as innovatively summarize the cutting-edge applications of AI in 3D pathology of lymphomas, and finally, we emphasize the development potentials and current challenges of AI in the field of lymphomas to promote precision lymphoma diagnosis and treatment by providing a theoretical foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.